

Linvoseltamab

| | |
|-----------|---|
| Cat. No.: | HY-P9989 |
| CAS No.: | 2408319-25-3 |
| Target: | CD3; TNF Receptor |
| Pathway: | Immunology/Inflammation; Apoptosis |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

Description

Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and CD3 epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models^{[1][2]}.

REFERENCES

[1]. Lee H C, et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma[J]. 2023.

[2]. Linvoseltamab. IMGT/mAb-DB.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA